P825: SOLUBLE FACTORS CORRELATED WITH CYTOKINE RELEASE SYNDROME (CRS) WITH IV VS SUBCUTANEOUS (SC) ALNUCTAMAB (ALNUC; BMS-986349; CC-93269) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

• Isaac Boss,
• Ethan Thompson,
• Allison Gaudy,
• Thi Minh Diem Vu,
• Colin Godwin,
• Michael Burgess,
• Sandy W. Wong,
• Luciano Costa

Affiliations

Isaac Boss

1 Bristol Myers Squibb, Translational Research, Seattle, United States

Ethan Thompson

2 Bristol Myers Squibb, Informatics and Predictive Sciences, Seattle, United States

Allison Gaudy

3 Bristol Myers Squibb, Clinical Pharmacology and Pharmacometrics, Summit, United States

Thi Minh Diem Vu

4 Bristol Myers Squibb, Early Asset Development, Princeton, United States

Colin Godwin

5 Bristol Myers Squibb, Early Clinical Development, Seattle, United States

Michael Burgess

6 Bristol Myers Squibb, Early Clinical Development, Princeton, United States

Sandy W. Wong

7 University of California, Department of Medicine, San Francisco, United States

Luciano Costa

8 University of Alabama, Division of Hematology and Oncology, Birmingham, United States